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4. Introduction 
Since its introduction in 1977 (1;2), percutaneous coronary intervention (PCI) has 
become the most frequent used treatment of symptomatic coronary artery disease 
with high procedural success (3) and advantages of short hospital stay and quick 
return to normal daily life activities. In selected cases PCI is performed as an 
outpatient procedure. 
Initial treatment with balloon angioplasty was limited by restenosis (35-45%) 
due to residual stenosis, early elastic recoil, negative remodeling and to some degree 
neointima formation. The high number of acute closure (5-8%) was another 
limitation, but this was dramatically reduced by the introduction of coronary stents, 
nearly abandoning the need for emergency coronary artery bypass surgery (CABG).  
Two important clinical problems still remain with the use of stents: subacute 
stent thrombosis and in-stent restenosis (ISR). Subacute stent thrombosis is a life 
threatening condition, but has been reduced to about 0.5% of patients using modern 
antithrombotic medication (4). Stents also reduce restenosis compared to balloon 
angioplasty (5-11), but restenosis rates in patients receiving stents may still be 20-
40%. In-stent restenosis is caused by proliferation of intima inside the stent and 
effective treatment requires prevention or suppression of this intima response.  
4.1 Pathophysiology of restenosis 
The vascular response to balloon angioplasty injury consists of four phases: thrombus 
formation, inflammation, proliferation and arterial remodeling. The luminal 
enlargement is caused by stretch of the entire arterial wall, while there is little 
compression of the atherosclerotic plaque (12;13). As a consequence of this stretch, 
variable degrees of dissection and dehiscence of the media as well as fracture and 
separation of the media from the adventitia evolve. Subsequent to the angioplasty 
injury there is an exposure of thrombogenic surface. Circulating inflammatory cells 
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(neutrophils, lymphocytes and monocytes) adhere to the injury site and migrate into 
the thrombus (14;15). These cells release growth factors like platelet derived growth 
factor, promoting smooth muscle cell (SMC) migration and proliferation and 
modulating the transition of SMC from a quiescent into mitotic phase. Macrophages 
produce matrix-degrading metalloproteinases. Inhibition of matrix-degrading 
metalloproteinases reduce the number of SMCs migrating into the intima (16;17). 
Several studies have demonstrated that proliferating adventitial cells also migrate into 
the intima (18;19). The role of the adventitia and collagen in the remodeling of the 
arterial wall has been increasingly recognized and geometric remodeling is accepted 
as a more important determinant of late loss than neointimal formation after balloon 
angioplasty (20).  
4.2 Treatment of restenosis: pharmacological approach 
Several animal models have been used to study a variety of pharmaceutical agents to 
reduce restenosis after angioplasty. Most often used are the rabbit iliac and porcine 
coronary models. An overstretch injury is performed by balloon angioplasty or stent 
implantation to either the iliac arteries in rabbit or coronary arteries in swine. A 
number of agents have been reported to have a beneficial effect on restenosis in 
experimental studies (21;22). In human trials most of these agents failed to influence 
on restenosis (23-27). This lack of effect may be explained by dissimilarity between 
the experimental models and the clinical situation and by differences in 
concentrations of the agents used in animal studies (28).  
4.3 Treatment of restenosis: mechanical devices 
A larger final minimal lumen diameter after angioplasty is related to a lower 
restenosis rate. Mechanical removal of the plaque (atherectomy) can be achieved by 
directional coronary atherectomy (DCA), by rotational atherectomy (RA) 
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(Rotablator) or by laser-assisted angioplasty. Implantation of stents provides a larger 
final lumen diameter by compressing the atherosclerotic obstruction. 
DCA removes tissue by directional cutting of the plaque, followed by balloon 
angioplasty. DCA is superior to balloon angioplasty in selected patients with discrete 
lesions when a final stenosis less than 10 % is obtained (29). A study comparing 
DCA prior to stent implantation with stent implantation alone showed advantages of 
the DCA treatment only in bifurcational stenosis (30). Overall restenosis rate was not 
reduced by DCA, while complications were reported to be more frequent (29). 
Therefore, routine use of DCA before stent implantation is not recommended.  
The rotational atherectomy device removes tissue by pulverizing inelastic 
tissue like calcified plaques by using a high speed rotating burr. Adjunctive 
angioplasty is used to optimize final lumen diameter. Several studies comparing RA 
and angioplasty have been carried out, but restenosis rate after 6 month was not 
significantly different (31). Rotational atherectomy is nowadays restricted to cases of 
heavily calcified lesions, ostial lesions or selected bifurcational lesions (32). 
 Laser atherectomy devices ablate tissue by delivering laser energy. Two types 
of laser systems exist: the ELCA system and the Ho:YAG system, using laser light 
with a different wavelength. Reduction in restenosis rates have not been 
demonstrated using laser atherectomy combined with angioplasty compared to 
balloon angioplasty alone (31;33;34). 
Coronary stents are endoluminal devices, initially introduced to treat 
threatening acute closure of the vessel by scaffolding large dissections. Stents have 
also shown to reduce restenosis not only in non-complex lesions (5;6), but their 
superiority over balloon angioplasty is also evident in saphenous vein graft lesions 
(7), chronic total occlusions (8;9), and ST-segment elevation myocardial infarction 
(10;11).  
The vascular response after stent implantation is different from balloon 
angioplasty. Stenting results in larger acute gain in luminal diameter and prevents 
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elastic recoil and negative remodeling of the vessel (35). On the other hand, stents 
provoke a greater absolute late luminal loss than angioplasty and carry the additional 
risk of thrombosis. Stents lead to chronic and prolonged damage of the vessel wall, 
resulting in pronounced neointimal hyperplasia (36). The degree of intimal 
hyperplasia is dependent on the extent of injury and of the type of stent (36).  
4.4 Treatment of in-stent restenosis: intracoronary brachytherapy 
In-stent restenosis is caused by neointimal proliferation and effective treatment 
requires prevention or suppression of this intima response. Current treatments like 
balloon angioplasty, atheroablative techniques and repeated stenting have not been 
effective in treating ISR. Intracoronary brachytherapy (ICBT) in patients with prior 
restenosis undergoing repeat coronary angioplasty has been shown to successfully 
reduce restenosis (37-41). ICBT given immediately after stent implantation does not 
prevent the restenosis rate (42;43). Serious concerns of this therapy like late 
thrombosis, an increased rate of myocardial infarction and restenosis at the edges of 
the irradiated zones have prevented its widespread use. However, there is clearly a 
beneficial short-term effect of brachytherapy after in-stent restenosis. Follow-up after 
the early experience studies suggested a reduced long-term effect (44), but these 
studies did not include the possible benefits of a broader clinical experience with 
brachytherapy. 
4.5 Prevention of in-stent restenosis: local drug-delivery, stent-
coatings 
An alternative way of counteracting in-stent restenosis is by reducing the 
development of neointima. Systemic pharmacological treatment demands high 
concentrations necessary to obtain sufficient effect locally at the dilated area and this 
may cause serious side-effects. Local drug delivery has the advantage of achieving 
high local concentration without systemic side-effects. It offers substantial benefit 
since the treatment can be delivered over time. However, initial clinical studies with 
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local drug delivery catheters (InfusaSleeve, Dispatch, Microporous Infusion Catheter) 
did not show benefit and initial enthusiasm for local drug therapy declined. 
 Since stents are the only devices to reduce restenosis rates, it seemed logical to 
deliver agents by stents. Drugs can be attached to bare stents but this concept has not 
yielded promising results (45).  A lot of efforts have been made to develop stents 
which were coated either by a biocompatible coating reducing neointima by itself or 
by a coating of synthetic polymers which could serve as a drug carrier. The early 
development of coated stents was hampered by the exaggerated inflammatory 
response and neointimal hyperplasia in animal models of synthetic polymers (46-48). 
Phosphorylcholine (PC) is a naturally occurring phospholipid in plasma membranes 
of blood cells, rendering them non-thrombogenic. PC derivatives have been reported 
to be non-thrombogenic coating medical devices (49-51). Phosphorylcholine is a 
zwitter ion and binds water, which makes the coated surface non-thrombogenic (fig. 
1). The biocompatibility of PC makes it interesting as a stent-coating to reduce 
intimal hyperplasia itself or serve as a drug carrier. The coating binds strongly to 
metal. 
Coatings like carbon, gold and silicon count also as biocompatible, of which 
gold (52) and carbon have been tested in animal models (53).  
4.6 Antioxidants 
The angioplasty injury causes expression of reactive oxygen species. They may act as 
vascular smooth muscle cell mitogens. Animal studies have shown that antioxidants 
inhibit both cell proliferation and negative arterial remodeling after angioplasty (54-
57). Recently it has been shown that the antioxidant probucol reduces restenosis after 
percutaneous balloon angioplasty in patients (58;59). Probucol also has been reported 
to reduce restenosis after stent implantation when given as combined treatment with 
cilostazol (60), while probucol alone does not affect restenosis rate after stenting (61). 
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Tetradecylthioacetic acid (TTA){CH3-(CH2)13-S-CH2-COOH} is a 3-thia fatty acid 
analogue in which a sulfur atom is located in the 3rd position in the carbon chain from 
the carboxyl end of a normal saturated fatty acid. The chemical structure of TTA is 
shown in fig. 2. TTA has been shown to possess antioxidant and antiinflammatory 
effects, inhibiting the oxidative modification of low-density lipoprotein (LDL) 
particles in vitro (62). A potential anti-proliferative effect of TTA has been reported 
(63). This fatty acid analogue may therefore have important actions on the arterial 
wall and modify the pathogenesis of restenosis. 
4.7 Early ambulation 
Coronary stents have reduced the risk for acute occlusion after PCI to <1%. Stent 
thrombosis occurs most often during the first week after implantation but has been 
reported later during the first weeks and year (64-66). The risk of subacute stent 
thrombosis is higher in patients with acute coronary syndromes than in elective 
patients (67). Prolonged hospital stay after the procedure is therefore not indicated in 
elective patients, provided low risk of bleeding at the puncture site. Bleeding 
complications are associated with choice of entry site, the diameter of the arterial 
sheath used, systolic hypertension, the dose of acetylsalicylic acid and the dose of 
heparin administered during the procedure (68-70). Because of early mobilisation and 
low bleeding risk, the radial approach has been proposed as the routine entry site. 
However, loss of pulse after radial cannulation has been described in 3% of the 
patients, compared to 0% using the femoral artery (71). Radial spasm is another, 
more frequent complication, causing discomfort and reducing procedural success 
rate. Heparin reduces intracoronary thrombosis and complications during invasive 
procedures (72;73). However, prolonged treatment does not improve outcome after 
angioplasty (74;75) and increases puncture site complications even at low doses 
(69;70). A number of vascular hemostasis devices (Vasoseal) have been developed to 
shorten immobilisation after femoral procedures.  
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Heparin effect can be monitored by activated clotting time (ACT). ACT <250 
seconds is associated with an increased risk for complications, which are rare in 
patients who have an ACT >300 seconds (72;76). After the procedure, femoral sheath 
removal is not recommended before ACT <175 seconds. Protamine sulphate  
antagonises heparin and has been used to treat bleeding complications after coronary 
interventions (77;78). The routine use of protamine after PCI at the end of the 
procedure could be a non-expensive and easy way to rapid sheath removal, provided 
it does not increase the number of coronary events such as subacute stent thrombosis. 
The development of a non-thrombogenic stent coating would in theory reduce the 
risk of thrombosis in conjunction with the use of protamine at the end of the 
procedure.  
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5. Aims of the studies 
The two major limitations of bare metal coronary stents have been thrombosis and 
restenosis. Acute and subacute stent thrombosis are life threatening conditions and its 
prevention often causes delayed hospital discharge. In-stent restenosis has been 
difficult to treat in the past. Consequently the aims of these studies were: 
5.1 To examine the arterial wall reaction and stenosis development after 
implantation of phosphorylcholine-coated stents in rabbit iliac and porcine coronary 
arteries. 
5.2 To assess the feasibility of reversing the heparin effect with protamine 
sulphate after implantation of a phosphorylcholine-coated coronary stent in order to 
avoid stent thrombosis and to permit future outpatient procedure. 
5.3 To assess the vessel wall reaction after balloon angioplasty injury in 
rabbits receiving oral supplements of the antioxidant TTA and to evaluate the 
myocardial contents and ratio of omega-3 and omega-6 fatty acids as an 
inflammatory index. 
5.4 To investigate the phosphorylcholine-coating as a carrier for TTA, its 
uptake and retention of TTA into the vessel wall and the vessel wall reaction to TTA 
in a porcine coronary model.  
5.5 To examine the long-term efficacy of a best-treatment strategy for 
intracoronary brachytherapy in patients with in-stent restenosis at high-risk for 
recurrence, in view of the shortcomings of phosphorylcholine, TTA or both to reduce 
restenosis. 
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6. Methods 
Paper 1, 3 and 4 describe experimental studies, paper 2 and 5 describe clinical 
studies. 
6.1 Experimental studies 
To study different treatment strategies interfering with the vessel wall healing 
response after the angioplasty injury, we used both the rabbit iliac and the porcine 
coronary model. Injury was performed either by balloon angioplasty or by 
implantation of a stent.  
Procedures were performed at the Vivariet, the animal laboratory of the Haukeland 
University Hospital. Animals were fed on standard chow diet without cholesterol 
supplementation and kept under standard environmental conditions. 
All animal study protocols were approved by the local ethical committee for animal 
care and use. 
6.1.1 The rabbit iliac model 
Chinchilla rabbits Chbb:CH were used in paper 1and 3. Anesthesia was induced by 
administering diazepam 4 mg/kg intraperitoneally after premedication of Hypnorm® 
0.5 mL intramuscularly. Repeat doses of 0.3-0.4 mL of a 1:1 mixture of Hypnorm® 
and diazepam were administered intraperitoneally if necessary. Heparin (100 IU/kg) 
was administered intra-arterially to achieve anticoagulation. Balloon angioplasty 
catheters were advanced to the iliac arteries over a 0.035 mm angioplasty guide wire 
via an introducer in the carotid artery. Overstretch injury was performed with a 
handcrimped stent on a balloon catheter (diameter 2.5 mm) or by an oversized 
angioplasty balloon (diameter 2.5 mm) to both iliac arteries using a pressure 
manometer to assure accurate and comparable pressures. Angiography was performed 
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before and after angioplasty using Hexabrix to confirm artery patency. The animals 
were allowed to recover and follow-up angiography was performed after 4 weeks 
(paper 1) or 10 weeks (paper 3). Analgetics (Buprenorfin (Temgesic®)) were given 
for the first 2 to 3 days, penicillin for 3 to 4 days to prevent post-procedure infections. 
The animals were killed by giving overdose pentobarbital intraarterially and the iliac 
arteries perfusion-fixed with 2% glutaraldehyde. 
6.1.2 The porcine coronary model  
In paper 1, both full-grown Göttingen minipigs and juvenile domestic crossbred 
swine were used, in paper 4 only domestic crossbred pigs. A peroral dose of 330 mg 
of acetylsalicylic acid was given the night before the procedure Anesthesia was 
induced by giving ketamine 10 mg/kg (Ketalar®), medetomadine 0.1 mg/kg 
(Dormitor®) and atropine 0.03 mg/kg intramuscularly. Isoflurane was given in a 
mixture of O2/NO2 (1:1) by nose cone until the animal was sufficiently relaxed to 
allow endotracheal intubation. Anesthesia was maintained by 1-1.5% isoflurane in 
O2/air. Blood pressure, heart rate, ECG and temperature were monitored 
continuously. During all procedures heparin (100 IU/kg) was administered intra-
arterially to achieve anticoagulation. Stents were delivered to the proximal parts of 
the coronary arteries on balloon catheters of diameter 3.0 mm (paper 1) or 3.5 mm 
(paper 4) at identical pressures using a pressure manometer. Analgetics (Buprenorfin 
(Temgesic®)) were given for the first 2 to 3 days, antibiotics (Penicillin/streptomycin 
combination) for 3 to 4 days to prevent post-procedure infections. Follow-up 
angiography was performed after 4 weeks. Animals were killed by an overdose of 
potassium chloride, the heart excised after a midline thoracotomy. The coronary 
arteries were perfusion-fixed at 100 mmHg using 2% glutaraldehyde or 4% 
formaldehyde. 
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6.1.3 Phosphorylcholine-coating 
The biocompatibility of the PC-coating was studied in paper 1. The PC-coating is 
composed of methacrylate polymers which serve as a backbone to which 
phosphorylcholine is attached. This coating was attached to disarticulated slotted tube 
stainless steel Palmaz-Schatz stents®, PS 153 (Johnson & Johnson) by BCP Dilatec 
Inc., UK. A PC-coated and a non-coated stent were randomized to implantation in 
either iliac artery of 8 rabbits and to the proximal part of the left anterior descending 
artery (LAD) or the left circumflex artery (LCx) of 10 pigs. Stents were deployed in a 
standard manner. 
6.1.4 The antioxidant Tetradecylthioacetic acid (TTA) 
Fourteen rabbits received either peroral supplementation of 800 mg TTA daily or 
standard diet (paper 3). The animals were pretreated with TTA for three weeks to 
ensure accumulation in the tissues, according to earlier studies with the antioxidant  
probucol (58;59). A dose of 800 mg daily was chosen based on earlier experiences 
with TTA in rats. In these rats a daily dose of 150 mg/kg changed the fatty acid 
composition of plasma significantly. TTA was dissolved in aceton and sprayed on 
food pallets. Blood samples were collected at baseline, at the time of the procedure 
and the time of euthanasia. Balloon angioplasty injury was performed to both iliac 
arteries in a standard manner. 
6.1.5  Local delivery of TTA using phosphorylcholine-coated stent as 
carrier 
The uptake, retention and vessel wall response to TTA-loaded PC-coated stainless 
steel stents was studied in a pocine coronary model. The drug loading and elution of 
these stents was also determined in vitro (paper 4). Stainless steel BiodivYsio® stents 
were coated with PC-coating of increased thickness of ca. 100nm (BCP Ltd Inc) (79), 
necessary to provide a reservoir to hold therapeutical loadings of drugs. The TTA 
content per stent was determined by gas chromatography after immersion in solutions 
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of different concentrations of TTA. TTA-loaded stents were then perfused in a 
dissolution bath to determine the release of TTA.  
Bare BiodivYsio® stents and BiodivYsio® stents loaded with TTA (25, 50 and 
100 mg/mL) were randomized to implantation in the right coronary and left 
circumflex artery in the same pig in 3 series of 6 pigs. Uptake of TTA into and the 
fatty acid composition of the coronary wall was determined for upto 28 days using 
the same model and compared to a non-dilated control vessel in the same animal. 
6.2 Clinical studies 
Two clinical studies were performed on different patient populations (paper 2 and 5). 
Studies were performed at the Coronary Intervention Center of the Haukeland 
University Hospital. Patients signed the informed consent and the study protocols 
were approved by the local ethics committee. 
6.2.1 Patient population 
In paper 2, all patients undergoing angioplasty to a single totally occluded coronary 
artery were evaluated for implantation of PC-coated Divysio stents and reversal of 
heparin by protamine. After succesful opening of the occlusion, fifty patients were 
included in the study meeting the following inclusion criteria: stable or medically 
stabilised unstable angina pectoris, reference artery diameter >2.5 mm and the length 
of the occlusion <15 mm. Patients with a left ventricular ejection fraction below 
<30%, occlusion of a vein graft or known adverse effects to protamine sulphate were 
excluded. 
In paper 5, patients with symptomatic in-stent restenosis in native coronary 
arteries or in aortocoronary venous bypass grafts were screened for treatment with 
intracoronary brachytherapy (ICBT). Patients were selected if they at least had one 
increased risk criterium for in-stent restenosis: vein graft lesion, ostial lesion, at least 
one previous treatment for in-stent restenosis in the same location, lesion length >20 
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mm, reference vessel diameter <3.0 mm or diabetes mellitus. Angiographic entry 
criteria included diameter stenosis ≥50% within the stent treatment site in vessels that 
were ≥2.5 to 5.0 mm in diameter. Exlusion criteria were unprotected left main lesion, 
unsuccessful PCI, acute myocardial infarction within 5 days, severe heart failure (EF 
<20%), refractory ventricular arrhythmias, and cardiogenic shock. Based on these 
criteria 48 patients were included in the study. Patients were referred for ICBT also 
from other interventional laboratories in Norway. 
6.2.2 Angioplasty procedure 
All angioplasty procedures were performed using 8F catheters via the femoral 
approach. Patients were pretreated with acetylsalicylic acid for at least 24 hours. 
After insertion of the arterial sheath, a bolus dose of 7.500 IE of heparin was 
administered to assure ACT > 300 sec. Clopidogrel treatment was started after 
conclusion of the procedure in study 2 (heparin reversal) to mimick a fast-track 
angioplasty as close as possible. Patients referred to brachytherapy started with 
clopidogrel at least 24 hours before the procedure and continued for 6 months or 
more to decrease the risk of late stent thrombosis. Standard angioplasty technique 
was used in both studies. Follow-up angiographies were performed using 6F catheters 
due to calibration for quantitative coronary angiography (QCA) (80).  
6.2.3 Divysio stent  
In study 2, a 15 mm PC-coated Divysio stent was implanted at a pressure of >12 
atmospheres after predilatation of the occluded artery. The Divysio® stent is a slotted 
tube laser cut stent composed of stainless steel comprising interlocking arrowhead 
design. The expanded stent covers 15% of the wall surface and is coated with 
phosphorylcholine, which adheres strongly to stainless steel. The PC-coating is 
described under 6.1.3. All the stents were handcrimped on commercially available 
angioplasty balloon catheters. Additional stents of the same type were implanted to 
the same lesion if clinically indicated at the operator’s discretion. 
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6.2.4 Protamine sulphate 
To study the antithrombotic property of the Divysio® stent, protamine sulphate 25 mg 
was administered intravenously after successful implantation of the stent. Special 
care was taken to inject protamine slowly to prevent side-effects.  
6.2.5 Intracoronary brachytherapy 
Brachytherapy was given as β-radiation, using The Galileo™ Intravascular 
Radiotherapy System (Guidant Corp). The stenotic segment was dilated carefully by 
using non-compliant balloon catheters at high pressure. Before delivering radioactive 
treatment, the angioplastic result was evaluated by angiography and by intravascular 
ultrasound to eliminate edge dissections, significant residual stenosis and incomplete 
stent apposition. Radiation therapy was given with a fixed dose of 20 Gy, radiation 
time was dependent on reference lumen diameter as measured by QCA and 
intravascular ultrasound (IVUS).  
6.3 Imaging methods 
6.3.1 Quantitative coronary angiography and intravascular ultrasound 
In the rabbit model (paper 1 and 3), angiography was performed in the anterior-
posterior view. Frames with optimal opification were selected for quantification. A 
digital electronic caliper (Sandhill, model EC-1) was used to measure lumen diameter 
of the iliac artery before dilatation, while maximal lumen diameter, reference 
diameter and balloon-to-artery ratio were measured after dilatation (81). A balloon 
angioplasty catheter dilated to rated pressure served for calibration. The contrast-
filled balloon was placed on the lower part of the abdomen in the same level of the 
dilated arteries. This method was validated by repeated measurements of the same 
balloon catheter expanded to rated pressures (table 1). At follow-up, minimal luminal 
diameter, reference diameter and stenosis were determined using the same method. 
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In the pig model (paper 1), single matched ‘best views’ from the angiography images 
were selected for digital quantitative analysis. Stenosis diameter (minimal luminal 
diameter in the stent) and reference vessel diameter were measured, and percent 
stenosis was calculated. The guiding catheter served for calibration (82). 
In both clinical studies QCA was performed using the CAAS II analysis system (Pie 
Medical BV, Maastricht, Netherlands). Calibration was achieved by measuring the 
guiding catheter. 
IVUS was performed with the Endosonics system, and quantitation performed by a 
technician blinded to the clinical data (paper 5). 
6.3.2 Preparing of the injured vessel segments in the animal studies 
To maintain the vessel structure post-mortem, the injured arteries were perfusion-
fixed at 100 mmHg with 2% glutaraldehyde (paper 1 and 3) or 4% formaldehyde 
(paper 4) after flushing with prewarmed (37 0C) and heparinized saline to clear the 
blood. Non-stented vessels were embedded in paraffin after dehydration in graded 
ethanol series, cut into sections and stained with hematoxylin-eosin or Verhoef-van 
Giesen elastin. Stented vessels were processed in methyl-methacrylate to solid 
blocks. A diamond-tipped rotary saw (Isomet 4000, Buehler) was used to cut the 
blocks into 100 µm cross-sections throughout the whole length of the stent. The 
sections were glued to slides and ground to 30 μm with the Metaserv 2000 grinder 
and grounded further to 10 μm and polished with the Biothin grinder (Buehler) (83).  
In paper 4, stented vessels were excised to determine uptake of TTA into and 
fatty acid composition of the coronary wall. The stents were then cut longitudinally 
and the tissue on both sides of the stent was removed and put in separate tubes for 
further analysis. Non-dilated vessels served as control. The samples were 
immediately frozen in liquid nitrogen and stored at –70 0C. 
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Myocardium and liver tissue (paper 3) were excised to study the effects of 
peroral substitution of TTA on fatty acid composition in rabbits. All samples were 
immediately frozen in liquid nitrogen and stored at –70 0C.  
6.3.3 Histomorphometry 
Histomorphometry was performed blinded to the randomisation after digital 
transition using computer-assisted planimetry (Leica Q500MC, software Qwin 01.02 
in paper 3 and analySIS vs 3.2, Soft Imaging System in paper 4). In balloon injured 
vessels (paper 3), areas surrounded by endothelium (lumen area), the internal elastic 
lamina and by the external elastic lamina were traced. Neointima was defined as the 
area between the lumen and the internal elastic lamina. Vessel area was defined as the 
area within the external elastic area. In sections of the stented segments (paper 1 and 
4), neointima was defined as the area between the lumen and the stent struts. The 
extent of arterial injury at each stent strut was determined according to the score 
proposed by Schwartz et al (84). Morphologic area stenosis was calculated as 100 x 
(1-Stenotic lumen area/Original lumen area). Stenotic lumen area was defined as the 
lumen vessel area, original lumen area as the area within the internal elastic lamina 
(paper 4). 
6.4 Statistics 
All data were presented as mean ± S.D for continuous variables and as n (%) for 
categorical data. 
Student’s t-test for unpaired data was used to compare groups with normally 
distributed data. This test was used in paper 1 to compare angiographic measurements 
between the PC-coated and non-coated stents. In paper 3 and 4 these observations 
were tested for significant differences between the TTA-group and the control group.  
Non-normally distributed data were analyzed by Mann-Whitney’s test, f.i. to compare 
histological data in paper 1.  
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Student’s t-test for paired variables was used to compare changes within the groups. 
Examples are changes in luminal diameter for a stent after dilatation and at follow-up 
(paper 1, paper 3) and changes in left ventricular ejection fraction and exercise tests 
before and after PCI (paper 2). 
 A causal connection between variables was tested by Pearson’s correlation test or 
linear regression analysis. An example is the relation between angiographic minimal 
lumen diameter and histological lumen area (paper 3) in rabbits.   
Logistic regression analysis was performed to assess independent risk factors for 
restenosis and major adverse coronary events (paper 5) during follow-up after 
intracoronary brachytherapy.  
In the same study, survival analysis was conducted using Kaplan-Meier method.   
All data analysis was performed using the SPSS program for Windows (versions 8.0, 
11.0 and 13.0). 
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7. Summary of the results 
Paper 1 
In this paper the vessel wall response to PC-coated stents was studied in the rabbit 
iliac model (n=8) and porcine coronary model (n=10). A PC-coated or a non-coated 
stent was deployed in either iliac artery of rabbits and in the left anterior descending 
artery and left circumflex artery of pigs. During follow-up no thrombotic stent 
occlusion occurred in the rabbits, but occlusion of a non-coated stent caused sudden 
death in one pig. After 4 weeks angiography in rabbits showed stent minimal luminal 
diameter 2.25±0.20 mm for the PC-coated stents versus 2.20±0.18 mm for the non-
coated stetns (p=NS), while histomorphometry showed no significant differences in 
intimal area, maximal intimal thickness nor luminal area between the two groups. 
Follow-up angiography in swine showed stent minimal luminal diameter was 
2.74±0.65 mm for the PC-coated group versus 2.55±0.73 mm for the non-coated stent 
group (p=NS) at 4 weeks. Intimal area was 1.51±0.97 mm2 versus 1.34±0.55 mm2, 
maximal intimal thickness 0.44±0.27 mm versus 0.47±0.38 mm, luminal area 
2.67±1.03 versus 2.42±1.27 mm2 (all p=NS) for coated and non-coated stent groups. 
In these two animal models, the PC-coating does not provoke arterial neo-intima 
formation nor decrease luminal diameter compared to stainless steel, while the 
coating does not seem to reduce restenosis. Its potential as a drug carrier should be 
further explored. 
 
Paper 2 
Immediate removal of the femoral artery sheath after coronary angioplasty may allow 
rapid mobilisation and reduces the number of in-hospital days. We studied the early 
and one month clinical and angiographic follow-up of patients having heparin 
antagonised with protamine after implantation of PC-coated metal (Divysio®) stents, 
followed by removal of the femoral artery sheath. Fifty patients (37 male, mean age 
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59±10 years) with stable angina pectoris and a single totally occluded artery (1 
unprotected left main stem, 15 LAD, 11 LCx, 23 RCA) underwent coronary 
angioplasty. Angiography was performed after 30 minutes and 1 month. One stent 
thrombus was detected after 30 minutes and was treated by balloon dilatation. One 
patient underwent emergency bypass surgery for non-stent related problems. Fourty-
six patients were mobilised after 5 hours, 2 patients after >5 hours. At one month 
there had been no major coronary endpoints, rehospitalisations, groin bleeding, or 
more thrombi. One episode of transient pulmonary oedema occurred after protamine 
injection. In conclusion, heparin may be reversed by protamine sulphate after the 
implantation of PC-coated stents without increased risk of stent thrombosis. It is not 
known if this also applies for uncoated metal stents. 
 
Paper 3 
Tetradecylthioacetic acid (TTA) is a synthetic long-chain fatty acid analogue that 
inhibits the oxidative modification of low-density lipoprotein particles in vitro. We 
examined the influence of TTA on the arterial wall response after balloon angioplasty 
injury in a rabbit iliac model. Fourteen rabbits were randomised to receiving either 
TTA fatty acids 800 mg daily perorally or to normal diet. Angioplasty was performed 
via right carotidotomy on both iliac arteries using an oversized balloon catheter, the 
TTA group being pretreated for 3 weeks. At 10 weeks follow-up angiography, 
minimal luminal diameter was 1.64±0.27 versus 1.13±0.52 mm for the TTA and 
control groups respectively (p<0.05). Histomorphometry did not show significant 
differences in intimal hyperplasia between the two groups (maximal intimal thickness 
0.19±0.10 versus 0.22±0.04 mm, p=NS and intimal area 0.32±0.12 versus 0.36±0.23 
mm2, p=NS for the TTA and the control groups respectively). Remodeling was 
0.52±0.32 versus 1.03±0.47 mm respectively (p<0.05). In the heart, the sum of the n-
3 fatty acids was 8.9±2.7 in the TTA group versus 4.3±0.2 mol% in the control group 
(p<0.05). The anti-inflammatory fatty acid index, calculated as (22:5 n-3 + 22:6 n-3 + 
20:3 n-6)/ 20:4 n-6, was 0.76±0.10 versus 0.25±0.03 for the TTA and control groups 
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respectively (p<0.05). In vitro TTA (100 µM) reduced the proliferation of human 
smooth muscle cell by more than 50%.  
 
Paper 4 
In this report the coronary wall response of a phosphorylcholine-coated stent loaded 
with the antioxidant Tetradecylthioacetic acid (TTA){CH3-(CH2)13-S-CH2-COOH} 
and the uptake of TTA in a porcine coronary artery injury model were studied. 
Eighteen-millimeter long premounted phosphorylcoline-coated stents were loaded 
with 3 different concentrations of TTA (25, 50 and 100 mg/mL) in series of 6 pigs 
each (Sus scrofa, weight 38.5±7.2 kg). A PC-coated and a TTA-loaded PC-coated 
stent were randomised to implantation in the right coronary and left circumflex artery 
in the same pig. The stents were removed after 4 weeks and prepared for 
histomorphometry. Uptake of TTA into the coronary wall was measured after 24 
hours, 7 days, 14 days or 28 days (2 pigs at each time point, Sus scrofa, weight 
44.3±7.3 kg) using the same model. TTA content per stent ranged from 32±20 
µg/stent using a solution of 25 mg/mL TTA concentration to 173±17 µg/stent using a 
100 mg/mL TTA concentration. The total amount left on the stent decreased from 
100 µg/stent to 40 µg/stent after 1 hour, to 6 µg/stent after 8 hours, whereas nearly all 
of the loaded TTA was eluted after 48 hours. During follow-up no death or subacute 
stent thrombosis occurred. Percent area stenosis was significantly higher in the TTA-
eluting stent group, 35.2±20.9 vs 27.5±17.0 %, p=0.03). Dose-related comparison 
showed a significantly increased intimal thickness (0.66±0.53 vs 0.29±0.26 mm, 
p=0.008) and intimal area (2.83±1.61 versus 1.58±0.91 mm2, p=0.004) for the 100 
mg/mL TTA stent group compared to the non-eluting stent group. TTA could be 
demonstrated in the vessel wall for up to 4 weeks. The anti-inflammatory fatty acid 
index (AIFAI), calculated as (docosapentaenoic acid + docosahexaenoic acid + 
dihomo-linolenic acid)/arachidonic acid, was suppressed to 0.65±0.27 compared to 
1.13±0.23 in control vessels (p<0.001). This was mainly due to a significant increase 
of arachidonic acid. TTA caused a dose-dependent intimal thickening and reduced 
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anti-inflammatory index contrary to expectations. Antioxidants may change property 
to pro-oxidants when used as a stent coatings. 
Paper 5 
In this study the efficacy of best treatment with intracoronary brachytherapy for in-
stent restenosis was evaluated in patients at high-risk for recurrence. Forty-seven 
patients with symptomatic in-stent restenosis with at least one or more increased risk 
criterion for recurrence were treated with beta-radiation.  The patients received best 
treatment based on avoidance of previously reported procedural risk factors for 
recurrence (incomplete stent apposition, dissection, geographical miss, damage to the 
non-injured vessel segment), deferring brachytherapy when provisional stenting was 
performed, the use of beta-radiation dose of 20 Gy and clopidogrel for at least 6 
months. Treatment was successful for all patients without in-hospital complications. 
Brachytherapy increased the total intervention procedure-time by 15±10 minutes. The 
in-stent restenosis length was 25.4±11.5 mm. The angiographic minimal luminal 
diameter after the intracoronary brachytherapy was 2.24±0.43 mm versus 0.75±0.58 
mm at baseline (p<0.05).  At 9-month follow-up minimal luminal diameter was 
1.93±0.48 mm (p<0.05 versus minimal luminal diameter at baseline). Binary 
restenosis was detected in six patients (13%). Target lesion revascularisation or target 
vessel (non-lesion) revascularisation was performed in seven patients (15%). No 
death, new myocardial infarctions or subacute stent thrombosis were observed. 
During 29.7±9.3 months follow-up, target lesion revascularisation or target vessel 
(non-lesion) revascularisation was performed in 17 patients (36%). Only one patient 
(2%) suffered from new myocardial infarction and no deaths were observed. 
Adoption of a best-practice protocol for the use of ICBT to treat in-stent restenosis 
can result in a safe and effectice clinical and angiographic outcome. However, long-
term results may be a limitation to a widespread use of this method. 
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8. General discussion 
The implantation of a stent is widely accepted as the most important way of reducing 
restenosis after percutaneous catheterbased treatment of stable or unstable coronary 
artery syndromes. In this thesis experimental and clinical studies assessed various 
interventions to further improve the results after metal stent implantation. The first 
step was to evaluate phosphorylcholine as a stent coating because of its two potential 
advantages, biocompatibility and reduced thrombogenicity. However, we found that 
it had no potential to reduce restenosis, but may be used with intravenous protamin 
sulphate injection to facilitate early arterial sheath removal and patient ambulation, 
without increased risk for stent thrombosis. 
 Phosphorylcholine also has the potential to carry other agents that may be 
effective to prevent restenosis. With this in mind, an antioxidant with 
antinflammatory action (TTA) was assessed for potential action on both main 
mechanisms of restenosis, remodeling and wall thickening. TTA was effective to 
prevent restenosis as demonstrated by its effect on remodeling, but had no efficacy as 
a stent coating. 
 Finally, brachyterapy does not prevent restenosis, but reduces restenosis 
during short-term follow-up, however the effect seems to diminish long-term. Studies 
are often performed when many investigators are in a learning phase, and the 
technique improves with time. Our best treatment strategy using brachytherapy did 
however not reduce cardiac events during follow-up. 
8.1 Methodological aspects 
8.1.1 Animal models  
In study 1 and 4 we used the porcine coronary injury model, the animal model of 
angioplasty and stenting most often applied to study restenosis (84;85) and to predict 
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response of new treatments in humans. The porcine coronary artery vasculature 
resembles that of humans in distribution and diameter, although pigs have fewer 
collaterals and the right coronary artery is less often dominant. The healing process 
after vascular injury in swine is comparable to humans, but the time course is much 
shorter in pigs. Neointima formation is formed typically during the first 28 days, 
whereas the same process takes 6-12 months in humans (86;87). The atherosclerotic 
process, causing coronary obstructions might explain the delayed healing process in 
humans. Stents are placed overlying plaques, which contain necrotic material with 
few smooth muscle cells and therefore might prolong recruitment of smooth muscle 
cells (88). Inflammation may play an additional role. In contrast, stents are implanted 
in normal arteries of non-adult pigs. The difference in life span might also play a role: 
human beings have an expected life age/span of more than 70 years, pigs 
approximately 16 years and rabbits 5-6 years. 
The rabbit iliac injury model was the other model we applied (paper 1 and 3) to 
study vessel wall healing. The rabbit model is easier to handle, has lower cost and has 
also been studied extensively. As in the porcine model the healing process after 
injury is usually completed after 4 weeks, but less intima and more matrix is formed 
(paper 1). Breaks in the internal elastic lamina after angioplasty are uncommon since 
iliac arteries are elastic arteries while coronary arteries in human and pigs are 
muscular arteries. 
A comparison of the neointimal area, as found in the papers 1, 3, 4 and another 
study published by our group (89), elucidates this clearly (fig. 3). The intimal 
response after balloon angioplasty in rabbits (paper 3) is less than after balloon 
angioplasty in pigs (89). Stenting provokes a stronger intimal reaction, but is most 
pronounced in pig coronaries (paper 1 and 4). 
Injury with an oversized balloon angioplasty catheter causes disruption of the 
internal elastic lamina with dissection into the media. After implantation of a stent, 
penetrating struts into the media cause a chronic inflammatory reaction (90). The 
increase of intimal thickness depends on the depth of the injury (36). 
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Animal models have been shown to be valuable in predicting clinical outcome of 
new treatment modalities. Negative responses in pigs correspond well to negative 
clinical trials, suggesting the model has good specificity. On the other hand, 
promising experimental studies do not always predict positive clinical trial results, 
indicating less high sensitivity of the model. Favourable results of inhibition of 
neointima in pigs at 28 days after brachytherapy (91), were followed by positive 
clinical findings after 6 months (40;41). Sirolimus and paclitaxel reduced formation 
of neointima at 28 days in pigs, this correlated well with promising results in humans 
(92-97). Many clinical trials of systemic pharmacological treatment have failed after 
positive experimental results. The large PRESTO-study is a recent example, tranilast 
not being effective in preventing restenosis, in contradiction to good preclinical and 
initial clinical results (24;98). 
8.1.2 Imaging methods 
Angiography has been the gold standard for visualizing vessels but wall pathology 
can be pronounced before lumen is decreased (99). Intravascular ultrasound depicts 
all the layers of the vessel wall, using high frequency piezoelectric transducers 
mounted on a 2.9 Fr catheter. Spasm is the most frequent complication related to 
IVUS in both animal models, although intravasal nitroglycerine reduces spasm. 
Potential damage to the stented segment is another concern in performing IVUS in all 
objects in experimental projects (100). Angiography is therefore a useful supplement 
to histological measurements, evaluating the degree of dilatation after balloon and 
stent injury and measuring late loss at follow-up. Negative remodeling is the most 
important factor in reducing vessel lumen after balloon angioplasty (20), while 
intimal hyperplasia causes lumen reduction after stent implantation (101). Combining 
angiographic late loss and histological measured intimal thickness gives information 
about lumen reduction of the vessel. Remodeling can be defined as angiographic late 
loss minus intimal thickness measured in the histology sections. This method was 
used in paper 3, validated by the significant correlation between the angiographic and 
histologic lumen (paper 3, fig. 1). 
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The concept of remodeling is well demonstrated in our studies. Angiographic 
late loss is largest in the balloon-injured segments, while it is minimal in the stented 
segments. Intimal thickness cannot alone explain lumen loss in the angioplasty 
studies, the difference is explained by negative remodeling of the vessel. In the 
stented rabbit and porcine arteries, angiographic late loss is comparable with intimal 
thickness, confirming that stents prevent either positive or negative remodeling (fig. 
4). 
The injured arteries were perfusion-fixed at 100 mm Hg with the purpose of 
maintaining the vascular structure as optimal as possible. Two types of fixatives were 
used. Glutaraldehyde, used in paper 1 and 3, penetrates slowly into the arterial wall 
but reacts rapidly with proteins and produces a stable fixation. Formaldehyde 
penetrates quicker into the tissue but reacts slower and more reversible with proteins. 
By perfusing the vessel with fixatives, both alternatives resulted in good tissue 
preservation due to the short distances for the fixatives to penetrate from the vessel 
lumen. Generally, fixation with glutaraldehyde impairs subsequent 
immunohistochemical staining due to altered properties of the antigens. Thus, 
formaldehyde fixation was preferred in paper 4 to enable subsequent 
immunohistochemical analysis, since most proteins preserve their immunoreactivity 
after fixation with formaldehyde.  
Non-stented vessels were embedded in paraffin, which gives a rather weak 
support to the tissue. This introduces possible artifacts due to compression of the 
tissue during cutting and to subsequent stretching of the sections, which may result in 
altered shape and cross-sectional volumes of the studied structures. However, by 
handling all material in the same manner, the risk for observing false differences 
between the groups should be minimized. 
Stented vessel specimens were embedded in methyl-methacrylate to achieve 
solid blocks, to enable cutting the stents with a diamond saw. 
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When assessing histomorphometry it is important to notice that balloon 
angioplasty injury provokes asymmetrical injury response, especially in pigs. Intimal 
area is therefore a more correct measure than intimal thickness. Both measurements 
were used in our studies.  
8.2 In-stent restenosis 
8.2.1 Shortcomings of coronary stents in clinical use 
Coronary stents are effective scaffolding devices to treat large dissections and thereby 
preventing acute closure in conjunction to angioplasty (102). Stents reduce restenosis 
in selected cases (5;6), but implantation is complicated with recurrent stenosis after 6 
months. To evaluate the long-term effects of coronary stents, we performed a 
prospective complete follow-up of all patients who had implanted a Palmaz-Schatz 
bare metal stent at Haukeland University Hospital (103). Patients treated by plain 
balloon angioplasty with a stent-like result during the same time period served as a 
control. A single 15 mm length Palmaz-Schatz stent was implanted in 167 patients 
(group 1), 336 patients underwent balloon angioplasty only (group 2), and 331 
patients had deployed a single disarticulated (7 mm length) ("half") Palmaz-Schatz 
stent (group 3). The indication for stenting was the absence of a stent-like result 
(dissection or residual stenosis >20%).  There were no baseline differences between 
the groups with respect to age, gender, target vessel, target vessel reference diameter 
or % stenosis. Lesion length was shorter in group 3. Major adverse cardiac events 
(MACE) during follow-up were defined as death, acute myocardial infarction (MI), 
or revascularisaton with PCI or CABG. Total MACE at a mean of 6.6±1.0 years was 
34.1%, 31.3% and 33.8% in group 1, 2 and 3 respectively (p=NS) (fig. 5). The 
percentage of target lesion revascularisation with PCI was 11.4%, 11.9% and 12.1%; 
CABG 6.0%, 4.8% and 6.6%; acute MI 7.2%, 9.2%, and 7.6%; and death 9.0%, 
5.7%, and 7.6%, respectively (p=NS). Thus, long-term prognosis is not different for 
patients with stents versus a stent-like result after balloon angioplasty. Short 
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(disarticulated) stents neither improved nor worsened the long-term MACE. These 
data indicate that stents need to be improved to perform better than balloon 
angioplasty during long-term follow-up. Effective stent-coatings could be the answer 
to this. 
8.2.2 Stent-coatings: PC-coating (paper 1) 
In the first study of this thesis, we evaluated the ability of phosphorylcholine to 
reduce the formation of neointima when used as stent coating in two animal models. 
Phosphorylcholine was applied as coating because of its, at that time, theoretical 
biocompatibility and antithrombotic properties. Many previous stent coatings 
provoked an intense inflammatory reaction (46). Our findings showed that 
phosphorylcholine did not have a pro-inflammatory effect, on the other hand it did 
not reduce neointima formation. An important conclusion therefore was that PC-
coating could serve as a carrier of an anti-restenotic drug. Other preclinical (104;105) 
and clinical studies (106) later confirmed our findings that PC-coated stents did not 
reduce restenosis rate compared to bare metal stents. Subsequently, PC-coating has 
only been promoted as a basic stent coating and as a drug carrier.   
8.2.3 PC-coated stents and early mobilization (paper 2) 
In theory, PC-coating should have favourable non-thrombogenic properties. 
Study 2 was a prospective, study of consecutive patients having a total coronary 
occlusion. This was the first study performed in patients in whom heparin was 
antagonized with protamin after PCI, therefore only patients with a total coronary 
occlusion were included. Already existing collaterals would reduce the risk of 
myocardial damage in case of acute stent thrombosis. Patients with an acute coronary 
syndrome were excluded, since documentation of the favourable effects of continued 
antithrombotics in these patients is overwhelming (107). 
Only one stent thrombosis occurred during 1-month follow-up. No bleedings 
or major hematomas were observed, while 48 of 50 patients were mobilized the same 
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day. In a subsequent comparable study of 429 patients, the authors also used 
protamine to enable immediate femoral sheath removal. Only 6 patients had minor 
hematomas and 1 patient required repair of pseudoaneurysm (108). Stents (bare-
metal) were used in 85% of the patients in this non-randomized study. Eight patients 
(1.9%) required emergency PCI or CABG prior to 48 hours, but details (e.g. stent 
thrombosis) were not given. Randomized studies with protamine have not been 
performed, thus it is not possible to conclude if the use of PC-coated stents would 
have reduced the number of revascularizations. While treatment effects always have 
to be confirmed by randomized clinical trials, complications to treatment may be 
assessed in observational studies. Our observational feasibility study shows that the 
rate of complications (stent thrombosis) was low using PC-coated stents with 
protamine. We cannot be sure that PC-coated stents perform better than bare metal 
stents, a randomized study would have required a very large number of patients. On 
the other hand, there was no indication of an increased rate of stent thrombosis with 
this regimen. 
Alternative methods of early femoral sheath removal include arteriotomy 
closure devices like Angio-seal, VasoSeal, Duett and Perclose. The safety of these 
closure devices versus mechanical compression was newly assessed in 2 meta-
analysis both including 30 studies published between 1991 and 2003 (109;110). In 
none of these meta-analyses the closure devices were more effective than mechanical 
devices. Groin complications after Vasoseal® vary from 10-34% (111), while only 
50% could be mobilised within a few hours after Vasoseal® (112). An important 
point of concern is the higher cost related to these devices. 
8.2.4 Inflammation and restenosis (paper 3 and 4) 
Balloon angioplasty and stent implantation both confer injury to the vessel. The 
endothelial surface is disrupted and denuded, promoting platelet activation, adhesion 
and deposition causing a fibrin-rich thrombus (113). It is quite clear that 
inflammation plays an important role in the subsequent wall thickening and stenosis 
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formation. Platelet activation expresses P-selectin, which mediates the adhesion and 
infiltration of monocytes into the vessel wall. β2-integrin Mac-1 plays a critical role 
in the adhesion of leukocytes and platelets. In a rabbit iliac stent model, inflammatory 
cells were seen immediately after stenting. The concentration of monocytes in the 
media was found to be proportional with the degree of neointimal thickening (114). 
Inhibition of β2-integrin Mac-1 reduced intimal thickening after both angioplasty and 
stenting in rabbits (115). In P-selectin-deficient mice inflammatory cells were not 
present in the carotid artery wall 4 weeks after ligation (116). Oxidative stress occurs 
early after angioplasty. Reactive oxygen species like free radicals and hydrogen 
peroxide are generated by the injured endothelium, activated platelets and 
neutrophils, leading to release of cytokines and growth factors which stimulate matrix 
remodeling and smooth muscle cell proliferation. Reactive oxygen species regulate 
the activity of matrix metalloproteinase, which are involved in matrix remodeling.  
Oxidative stress is also involved in cross-linking of collagen fibers, which is an 
important factor in negative remodeling. We demonstrated a reduction in late lumen 
loss in balloon injured iliac arteries of rabbits that got supplements with the 
antioxidant TTA.  
The anti-inflammatory fatty acid index (AIFAI), calculated as (docosapentaenoic acid 
+ docosahexaenoic acid + dihomo-linolenic acid)/arachidonic acid, was significantly 
higher in the myocardium of the control group compared to the TTA group. This 
index reflects the relation between the omega-3 fatty acids possessing anti-
inflammatory and anti-thrombotic properties and the omega-6 fatty acids being 
proinflammatory and prothrombotic (117). A higher index is indicative for an 
increased anti-inflammatory status. We propose that the AIFAI seems to be a reliable 
marker of inflammation after PCI as this index was increased in relation to positive 
remodeling in paper 3 and decreased with increased vessel wall thickening in paper 4. 
As demonstrated in paper 1, PC-coating could be used as a drug carrier. Local 
drug delivery has the advantage of administering high concentration of drugs at the 
site of injury over time without systemic side-effects. In vitro, TTA had anti-
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proliferative properties while TTA reduced the negative remodeling in vivo (paper 3). 
In the same model, TTA was shown to have anti-inflammatory activity. In vitro 
testing showed that TTA could easily be bound to and released from PC-coating 
(paper 4). TTA was demonstrated in the arterial wall for up to 4 weeks, but local 
delivery of TTA did not reduce the formation of neointima after stent implantation. 
At the highest concentration, TTA increased intima proliferation compared to PC-
coating only. The AIFAI was suppressed in the coronary arterial wall after 
implantation of TTA-eluting stents compared to controls (paper 4). Thus, when used 
as a stent coating on a phosphorylcholine-coating, TTA seems to act 
proinflammatory. 
8.2.5 Intracoronary brachytherapy (paper 5) 
Intracoronary brachytherapy has been shown to reduce neointimal proliferation in 
patients with in-stent restenosis, either administered as β-radiation or as γ-radiation. 
The adverse effect of late stent thrombosis is prevented by the long-term use of 
clopidogrel as we showed in our study (paper 5). We postponed brachytherapy for a 
month when a new stent was implanted to permit endothelialization and avoid acute 
stent thrombosis. By applying careful dilatation within the stent, using IVUS and 
appropriate positioning of the radiation source, we reduced restenosis to 13%, despite 
the patients were at high risk of recurrence. The favourable effects of intracoronary 
brachytherapy have been confirmed after 3 years (38), but an increasing number of 
target vessel revascularization has been described at 5 years, although the total 
number of MACE remained lower than in the placebo group (118). This late increase 
of target vessel revascularization (“late catch-up”) is a point of concern, also because 
it is known that vessel injury can occur many years after therapeutic radiation 
exposure (119;120). In animal models, brachytherapy inhibits neointimal formation 
for up to three months, with evidence of incomplete healing. At six month healing is 
completed and brachytherapy failed to show benefit, due to neointimal growth (121). 
Another point of concern is the logistics linked to the intracoronary brachytherapy, 
requiring the presence of nurses, cardiologists, oncologist and radiophysicist. 
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Study 5 was designed to test the efficacy of intracoronary brachytherapy in 
patients with in-stent restenosis at high risk of recurrence eliminating all the factors 
which can contribute to late failure. An appropriate control arm would have been 
patients with in-stent restenosis treated with a drug-eluting stent. However, drug-
eluting stents were not available in daily clinical practice at the start of the study. On 
the other hand, a great advantage of this study was that we implemented all the 
previous published experience with pitfalls of brachytherapy in our protocol (best 
treatment strategy).  
Very recently published studies have shown a favourable effect of both sirolimus 
and paclitaxel eluting stents compared to intracoronary brachytherapy on clinical as 
well as angiographic end-points in patients treated for in-stent restenosis (122;123). 
The rate of MACE after brachytherapy was higher in both studies (21.6% and 20.1%) 
than in our study (14.9%). Rates of MACE after sirolimus and paclitaxel eluting 
stents were 12.4% and 11.5%. Thus, the future place for ICBT may still be 
undecided. 
Intima inhibiton of sirolimus-eluting stent is not sustained in the pig model (124). 
Bearing in mind the diminishing effects of brachytherapy on the long-term, caution is 
necessitated using drug-eluting stents in human-beings unlimited. Delayed 
endothelialization might cause late stent thrombosis (125;126), while there is a 
tendency to use longer stents. Stents initiate a chronic inflammation, but the anti-
proliferative effect of drugs could be time-limited. Recent analyses also from 
registries have in fact suggested a significantly increased rate of late stent thrombosis 
compared to metal stents (127). 
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9. Conclusions 
The conclusions of the studies in this thesis were: 
9.1 PC-coating of stainless steel stents does not provoke arterial neo-intima 
formation in rabbit iliac and porcine coronary arteries. The coating does not reduce 
stenosis compared to stainless steel. 
9.2 After the implantation of a PC-coated stent, reversal of heparin with 
protamine sulphate does not cause stent thrombosis in patients with single vessel total 
occlusions and permits the angioplasty to be performed as an outpatient procedure. 
9.3 Peroral supplements with TTA is associated with less neointima formation 
due to positive arterial remodeling after balloon angioplasty injury in rabbit iliac 
arteries. Increase of the anti-inflammatory index in the myocardium suggests an anti-
inflammatory action of TTA. 
9.4 TTA was easily loaded onto a PC-coated stent. TTA loaded BiodivYsio® 
stents did not reduce the vessel wall reaction after implantation in the coronary 
arteries. There was a significant association between the TTA dose and vessel intimal 
area. TTA seems to act proinflammatory when delivered to the vessel wall via a 
metal stent. 
9.5 Intracoronary brachytherapy performed according to best treatment criteria 
confers short-term benefits for the treatment of in-stent restenosis in patients at high 
risk for recurrence, but an increased long-term recurrence rate may be a limitation. 
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Table 1 Repetitive measurements of angioplasty balloon catheter with diameter 
of 3.0 mm, inflated at 8 atm. 
 Day 1 Day 2 
1st inflation 3.04 3.03 
 2.99 2.97 
 2.92 2.94 
 2.96 3.00 
 3.00 2.97 
Mean 2.98±0.05 2.98±0.03 
Coefficient of variation 1.5% 1.1% 
2nd inflation 2.96 2.95 
 3.02 2.98 
 3.02 2.97 
 2.97 2.98 
 3.01 3.00 
Mean 3.00±0.03 2.98±0.02 
Coefficient of variation 0.6% 0.6% 
Mean of all measurements 2.98±0.03  
Coefficient of variation 1%  
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Figure 4 
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Figure Legend 
Figure 1 
The chemical structure of the phosphorylcholine head group. The molecule is a 
zwitterion with a positive loaded charged quaternary nitrogen-group and a negative 
charged phosphate-group within the same molecule. Overall the molecule is neutral. 
Figure 2 
The chemical structure of Tetradecylthioacetic Acid. 
Figure 3 
Graphical summary of data from the 3 experimental studies in the thesis (study 1, 3 
and 4)  and another study published by our group (89). Data markers represent 
averages of intimal area from these studies. On the left side of the break balloon 
angioplasty studies, on the right side stent studies. The intimal response after balloon 
angioplasty in rabbit iliac arteries (paper 3) is less than after balloon angioplasty in 
pig coronary arteries. Stenting provokes a stronger intimal reaction, but is most 
pronounced in pig coronary arteries (paper 1 and 4).  
R= rabbit, P= pig, TTA= Tetradecylthioacetic acid, PC= phosphorylcholine. 
Figure 4 
Graphical summary of data from the 5 studies in this thesis and another study 
published by our group (89). Data markers represent averages of angiographic late 
loss and maximal intimal thickness as measured by histomorphometry. Angiographic 
loss is largest in the balloon-injured segments, while it is minimal in the stented 
segments. Intimal thickness alone cannot explain late lumen loss in the balloon 
angioplasty studies (paper 3 and (89)), the difference is explained by negative 
remodeling of the vessel. In the stented rabbit and porcine arteries (paper 1 and 4), 
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angiographic late loss is comparable with intimal thickness, confirming that stents 
prevent remodeling. On the right side of the break angiographic late lumen loss 9 
month after balloon angioplasty and brachytherapy of in-stent restenosis (paper 5) 
and 1 month after implantation of a Divysio stent after opening of a totally occluded 
coronary artery (paper 2). 
R= rabbit, P= pig, H=human, TTA= Tetradecylthioacetic acid, PC= 
phosphorylcholine, ICBT= intracoronary brachytherapy. 
Figure 5 
Kaplan-Meier survival curves for major cardiac events (death, myocardial infarction 
or revascularisaton with coronary artery bypass surgery or percutaneous coronary 
intervention) for patients treated with balloon angioplasty (POBA), implantation of a 
disarticulated Palmaz-Schatz stent (7 mm PS) or a 15 mm Palmaz-Schatz stent (15 
mm PS). 
 
